Search Within

Jenessa Nyasha Holder

Formats
  1. Meeting Abstract (7)
Groups
  1. Department of Medicine (7)
  2. Advanced Practice Providers (4)
  3. Melanoma and Immunotherapeutics Service (4)
  4. Nursing (4)
  5. Solid Tumor Oncology Division (4)
  6. Bone Marrow Transplant (3)

More Groups

People
  1. Aya Haggiagi (4)
  2. Bianca Santomasso (4)
  3. Margaret Callahan (4)
  4. Rachna Malani (4)
  5. Samuel Briggs (4)
  6. Yelena Shames (4)

More People

Years
  1. 2020 (1)
  2. 2019 (2)
  3. 2018 (2)
  4. 2017 (2)
Publications
  1. Biology of Blood and Marrow Transplantation (2)
  2. Clinical Lymphoma, Myeloma and Leukemia (1)
  3. Journal for ImmunoTherapy of Cancer (1)
  4. Journal of Clinical Oncology (1)
  5. Neuro-Oncology (1)
  6. Neurology (1)
Publishers
  1. Elsevier Inc. (3)
  2. American Society of Clinical Oncology (1)
  3. Biomed Central Ltd (1)
  4. Lippincott Williams & Wilkins (1)
  5. Oxford University Press (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Improved quality of life with interleukin-6 (IL-6) blockade with siltuximab peri-autologous hematopoietic stem cell transplantation (AHCT) in older patients with multiple myeloma (MM)
    Meeting Abstract

    Shah, G. L.; Murata, K.; Holder, J.; Marcello, L.; Cho, S.; Hoover, E.; Chung, D. J.; Dahi, P. B.; Lahoud, O. B.; Scordo, M.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Reducing symptom burden in older patients with multiple myeloma (MM) using interleukin-6 (IL-6) blockage peri-autologous hematopoietic stem cell transplantation (AHCT)
    Meeting Abstract

    Shah, G. L.; Kosuri, S.; Holder, J.; Hoover, E.; Chung, D. J.; Dahi, P. B.; Scordo, M.; Landau, H.; Giralt, S. A.
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Interleukin-6 (IL-6) blockade with siltuximab peri-autologous hematopoietic stem cell transplantation (AHCT) may reduce symptom burden by altering the cytokine milieu in older patients with multiple myeloma (MM)
    Meeting Abstract

    Shah, G.; Holder, J.; Cho, S.; Murata, K.; Devlin, S.; Hoover, E.; Chung, D.; Dahi, P.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Neurologic immune related adverse events (irAEs) in patients treated with immune checkpoint blockade
    Meeting Abstract

    Santomasso, B.; Haggiagi, A.; Malani, R.; Maher, C. A.; Holder, J. N.; Shames, Y.; Wilcox, J.; Flynn, J.; Briggs, S.; Panageas, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Neurologic immune related adverse events (irAEs) in patients with metastatic solid tumors treated with immune checkpoint inhibitors: A single institution retrospective analysis
    Meeting Abstract

    Malani, R.; Haggiagi, A.; Holder, J.; Shames, Y.; Briggs, S.; Callahan, M.; Santomasso, B.
    Neurology (2018)

    Fulltext@MSK | Save
  • Neurotoxicity in patients with metastatic solid tumors treated with immune checkpoint inhibitors: A single institution retrospective analysis
    Meeting Abstract

    Santomasso, B.; Malani, R.; Haggiagi, A.; Holder, J.; Shames, Y.; Briggs, S.; Callahan, M.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • The development of neurologic immune related adverse events (irAEs) in patients with metastatic solid tumors treated with immune checkpoint inhibitors: A single institution retrospective analysis
    Meeting Abstract

    Malani, R.; Haggiagi, A.; Holder, J.; Shames, Y.; Briggs, S.; Santomasso, B.; Callahan, M.
    Neuro-Oncology (2017)

    Fulltext@MSK | Save